Since active EGFR mutants are sensitive to small-molecule tyrosine kinase inhibitors (TKI), a subset of NSCLC driven by active EGFR mutants is usually treated with TKI erlotinib and gefitinib. Here, EGFR is linked to non-small cell lung carcinoma.